[The immune cytochemical evaluation of reaction of phytohemagglutinin stimulation of lymphocytes with monoclonal antibodies Ki-67].

The article proposes new (immune cytochemical) mode of evaluation of reaction of blast-cell transformation of human lymphocytes under their stimulation with phytohemagglutinin instead of standard radiometric method using 3H-thymidine as a marker. The reaction was assessed by means of luminescent microscope under indirect immunofluorescence using nuclear antigen Ki-67 as a marker of proliferating cells. The Ki-67 was detected using monoclonal antibodies Ki-67. The functional capacity of lymphocytes was evaluated by amount of visualized (luminescent) Ki-67 positive cells appearing after three day stimulation of proliferation with phytohemagglutinin. The comparison was made between immune cytochemical (with Ki-67 marker) and radiometric (with marking by 3H-thymidine) methods of phytohemagglutinin stimulation of lymphocytes. The article presents substantiation of advantage of immune cytochemical method of evaluation of reaction of blast-cell transformation of human lymphocytes as compared with radiometric method concerning possibility of its broader implementation in laboratory practice.

[The levels of key nucleolar proteins in the lymphoid cells of healthy individuals and patients with lymphoproliferative diseases].

Immunocytochemical staining with specific antibodies was used to study the expression of three nucleolar proteins (fibrillarin, B23/nucleofozmin, and SURF6), which were involved in pRNA maturation, in the lymphoid cells of healthy individuals and patients with lymphoproliferative diseases and to compare it with the expression of the known proliferation marker Ki-67 protein. The results indicated that fibrillarin was detectable at the comparable level in the lymphoid cells of the patients and in the peripheral blood lymphocytes of the healthy individuals. In one fourth of the patients, the proportion of cells containing B23/nucleofozmin was noticeably higher than that in the lymphocytes of donors; however, there was no great difference in patients with different types of the disease. The number of SURF6-positive cells was directly correlated with that of Ki-67-positive cells. The maximum level (47-67%) of SUR6-positive lymphoid cells was found in splenic lymphosarcomas and mantle cell lymphoma. The findings suggest that SURG6 protein may be of additional diagnostic and prognostic value.

[Antibodies to synthetic fragments of nucleophosmin for the specific detection of its monomeric and oligomeric forms].

Immunoactive fragments corresponding to the N-terminal (19-36) and C-terminal (283-294) regions of the NPM1.1 isoform of nucleophosmin and their shortened fragments were chosen and synthesized. Rabbits were immunized with free full-size peptides and their protein conjugates. Antibodies produced against the 19-36 and 283-294 peptides were purified by affinity chromatography on bromocyanogen-activated sepharose that was preliminary conjugated with the synthetic peptides. An analysis of immunoblots of lysates of the HeLa and Ramos cells demonstrated that the antibodies produced against the 19-36 peptide detected the monomeric form of nucleophosmin, whereas the antibodies against the 283-294 peptide predominantly revealed its oligomeric form. It was established by immunocytochemical analysis that the antibodies induced by the 19-36 peptide stained the nucleoplasm and perinuclear space of the cytoplasm of the HeLa and Ramos cells, but did not stain the nucleoli, while the antibodies against the 283-294 peptide stained only the nucleoli of the same cells. On the basis of these results, one could propose that the monomeric and oligomeric forms of nucleophosmin were located in the nucleoplasm and nucleoli of the examined cells, respectively. Thus, antibodies which can predominantly detect monomeric and oligomeric forms of nucleophosmin were produced for the first time. An analysis of the monomeric-oligomeric state and the location of the nucleophosmin in tumor cells could be performed using these antibodies.